Michael J. Carvan III is a Shaw Professor at the University of Wisconsin-Milwaukee School of Freshwater Sciences with a diverse training background with a BS in Marine Biology, MS in Oceanography, PhD in Toxicology, and Postdoc work in Environmental Genetics. His research is focused on (epi)genome-environment-disease/dysfunction interactions and identifying pathways that influence sensitivity and resistance to environmental chemicals, especially those that cause birth defects or developmental problems. I primarily use zebrafish as an experimental system to explore biomedical and ecological toxicology topics.

Professor Eugene Jamot Ndebia is an esteemed academic specializing in Medical Physiology, Epidemiology and Biostatistics. With an NRF C3 rating, he is recognized for his impactful contributions to research and teaching. He currently serves as the Chairperson of the Human Research Ethics Committee (WSU-HREC) and leads the Cancer Epidemiology Research Group (CERG) within the Faculty of Medicine and Health Sciences at Walter Sisulu University, South Africa. Prof. Ndebia’s research primarily focuses on prevention strategies and the early detection of cancers, emphasizing interventions that save lives in vulnerable populations. His expertise extends to a wide range of public health challenges, particularly in low-resource settings. His work has garnered significant recognition, with an impressive publication record that includes numerous peer-reviewed articles cited extensively in academic literature. As a dedicated mentor, Prof. Ndebia has guided many postgraduate students, fostering the next generation of researchers and health professionals. His ability to translate complex epidemiological concepts into actionable insights has inspired his mentees to pursue impactful careers. With his extensive experience, scholarly achievements, and dedication to mentorship and community service, Prof. Eugene Jamot Ndebia remains a leading figure in the fields of Epidemiology and Biostatistics, contributing significantly to global efforts to improve health outcomes.

Dr. Yun Tam, born and raised in Hong Kong, earned his bachelor’s degree in biology from the University of Minnesota and a Master’s and Ph.D. in Pharmaceutical Sciences from the University of British Columbia. A recognized expert in pharmacokinetics, Dr. Tam holds six U.S. patents, including two international patents, and has published over 100 refereed articles and book chapters. He is an invited speaker at international conferences and serves on the Editorial Boards of the Journal of Pharmaceutical Sciences and Drug Metabolism and Disposition. He is also a Review Editor for Frontiers in Pharmacology and a member of the College of Reviewers at the Canadian Institutes of Health Research. Dr. Tam was a professor at the University of Alberta’s Faculty of Pharmacy & Pharmaceutical Sciences for 20 years, where he received the MaCalla Professorship for his research in predictive pharmacokinetics. He supervised 15 graduate students, received two undergraduate teaching awards, and served as a visiting professor at Roche, Basel. Dr. Tam also trained pharmaceutical scientists worldwide and consulted for multinational pharmaceutical companies. As an entrepreneur, Dr. Tam founded Kinetana, listed on the Hong Kong GEM Board in 2002, and Novokin Biotech in 2004. In 2006, he co-founded SinoVeda Canada Inc. with Dr. Nuzhat Tam-Zaman, creating the Pharmaceutical Platform Technology (PPT®), which combines botanical therapies with modern pharmaceutical science. Recently, AI has been incorporated into PPT to enhance precision product development. SinoVeda’s first botanical pharmaceutical candidate, SCI-RC-1341, for postmenopausal symptoms, was acquired in 2021. Dr. Tam has developed 14 NNHPD-approved consumer health products and botanical pharmaceuticals such as Ginkgo biloba and Panax ginseng, approved by Bangladesh’s health authority—a first in the country. His products, including Cordyceps, Lingzhi, Proflexa, and Eczema Rescue, are also sold in Hong Kong. SinoVeda’s Rx pipeline includes cannabis-based cancer treatments, alopecia therapies, and solutions for Long COVID. Two liver cancer candidates, SCI-0502 and SCI-1172, have shown efficacy equivalent to or exceeding sorafenib in preclinical studies, with improved safety. Antico, branded as Cordyva in North America, was launched in Canada in October 2024 as a Long COVID therapy after its success in Hong Kong. Preliminary results show significant improvement in 11 Long COVID symptoms. Dr. Tam continues to innovate at the intersection of traditional medicine and modern technology, addressing pressing global health challenges.

Dr. Sanjay Gupta is a Professor and holds Carter Kissell Endowed Chair in Urologic Oncology in the Department of Urology at Case Western Reserve University and the position of Research Director at the Urology Institute, University Hospitals Cleveland Medical Center. He also holds secondary appointments in the Departments of Pharmacology, Pathology, Nutrition and Division of General Medical Sciences at Case Comprehensive Cancer Center. Dr. Gupta had a joint appointment as Research Scientist from 2015 to 2020 at the Louis Stokes VA Medical Center, Cleveland, Ohio. Dr. Gupta obtained faculty position in 2002 at Case Western Reserve University, School of Medicine. Dr. Gupta’s research involves basic, translational and clinical areas of focus. In basic research his focus is to understand the risk factors and mechanisms of prostatic, breast, kidney and bladder diseases and develop appropriate biomarkers for early detection and prognosis. Translational research focus is to identify novel targets to monitor the efficacy of various synthetic and natural small molecules and develop them as chemo preventatives/therapeutics. His clinical research interests are translation of bench research to its application in clinics. Dr. Gupta has authored some 200 publications, including book chapters, research articles and reviews, and has spoken at several occasions in cancer prevention symposium, seminars and meetings both nationally and internationally. He has been serving in various study sections at National Cancer Institute (NCI) and Department of Defense (DOD), and other councils around the globe. He also serves on the Editorial board as well as reviewer for several prestigious scientific journals. His innovative research on basic and translational aspects has been featured on NBC-5 news and highlighted in the Plain Dealer, and American Association for Cancer Research, and American Urological Association press release.

Dr. Dan Safarpour received a B.S. in Chemistry in 1991 from the University of Arkansas, Fayetteville and a Ph.D. in Environmental Analytical Chemistry in 2001 from Rutgers University, Cook College, New Brunswick, New Jersey. Dr. Dan Safarpour started his professional career as residue chemist atAltheimer Laboratory of the University of Arkansas in Fayetteville, Arkansas. In 1993, he began employment with American Cyanamid Company, Princeton, New Jersey as an Analytical Chemist in the Toxicology Analysis laboratory. Later, within Cyanamid Global Research Center, he moved to other research group called Metabolism, Residue, Environmental Fate and Eco-Toxicology (MREE) Group as a Residue Chemist/Study Director. In 2000, American Cyanamid Company was acquired by BASF Corporation, at which time he joined the Formulations Analysis Group. In September 2001, he joined Taxolog, Inc, a pharmaceutical/biotechnology startup company. As a group leader at Taxolog, he was brought on-board to build an analytical group capable of conducting formulations analysis support as well as metabolism and bioanalytical to determine metabolite structures to protect company IP on pharmaceutically active metabolites and co-drugs. Dr. Safarpour led his team in compiling analytical R&D and dossier preparation for filing several IND, CTX and aNDA in partnership with Pfizer corporation. Dr. Safarpour has been published in journals such as Journal of Pharmaceutical and Biomedical Analysis (JPBA), Journal of Chromatography, Electrophoresis, Journal of Associations of Officials in Analytical Chemistry (JAOAC) and Journal of Pesticide Science. Per invitation from US-EPA regulatory bodies, Dr. Safarpour has contributed a chapter on Application of Capillary Electrophoresis to Pesticide Analysis to the Encyclopedia of Agrochemicals. Dr. Safarpour has given numerous oral presentations in national and international conferences in the areas of separation sciences, process and formulations analysis, human and plant metabolism, bioanalytical, and residue chemistry. His presentations have focused on the use of cutting-edge technologies such as UPLC, HPLC, CE, and GC, as well as UPLC-MS-QTOF, HPLC-MS-Triple Quad platforms and CE-MS. Dr. Safarpour has chaired symposium in peptide-protein friendly instrumentations arena, judged poster presentations at ACS functions such as the Triangle Chromatography Discussion Group (TCDG). Since 2003 until 2015, Dr. Safarpour has served on the peer review committee for prestigious journals such as JPBA, JAOAC and Electrophoresis. In early 2009, Dr. Safarpour, with former colleagues, employees founded a new life sciences contract research organization called Symbiotic Research, LLC. In 2017, he sold Symbiotic Research to a German conglomerate-Tentamus GmbH. In 2018, together with Tentamus GmbH, Dr. Safarpour acquired animal research facility Genesis Midwest, LLC out of Wisconsin USA to enable Symbiotic Research to provide in-life and analytical package study services to its global Animal Health and Agrochemical clients. In 2014, Dr. Safarpour was hired by International Atomic Energy Agency (IAEA) Food Safety division as an “Expert Lecturer” to consult the agency by traveling to developing countries and guiding the subject nations on matters related to building laboratories and laboratory infrastructures capable of analyzing agricultural food products by LCMS and ultimately helping those nations to be able to export their raw agricultural products globally in an attempt to expand their GDP growth and aid in global food sustainability.

Quinn Hofmann has been working as a toxicologist in the medical device field for the past 5 years. After obtaining toxicology and biochemistry degrees at Minnesota State University in Mankato, he was introduced to medical device biocompatibility while supporting 3M corporate toxicology Healthcare Business Group. He started working as a toxicology associate at Medtronic’s Physiological Research Lab in 2019, and was promoted to Senior Toxicologist when Medtronic’s new centralized Toxicology and Biocompatibility function at GLS was created in 2022. Since joining the new corporate toxicology function, he has been supporting Medtronic’s different operating units authoring toxicological risk assessments, assessing the impact on biocompatibility from material or manufacturing process changes, the biological safety of new products, and supporting submissions for market approval. His particular professional areas of interest are computational toxicology, such as in silico QSAR modeling, validation of new alternative methods, and looking for ways to assess novel materials.

Dr. Frank Breveis a clinical pharmacist with extensive experience across various healthcare settings, including hospitals, long-term care facilities, dialysis centers, surgical centers, assisted living, medical day care, PACE programs, narcotic treatment programs, and behavioral health facilities. They also consult for the pharmaceutical and biotechnology industries, as well as state and federal government agencies. Key areas of expertise include Medication Therapy Management, optimizing drug use to promote rational therapy and reduce adverse event risks, inspections and regulatory compliance, and the development and review of policies and procedures. They are also involved in Quality Assurance, Continuous Quality Improvement, pharmaceutical outcome studies, and legal consulting in medical malpractice and product liability cases. Dr. Frank Breve specializes in geriatrics (board certified), psychiatry/neurology (expert in psychopharmacology), oncology (with teaching hospital experience), nephrology (Pharma renal division experience), and drug diversion risk reduction, having served as a consultant for the United States Department of Justice and the Drug Enforcement Agency. Their work spans a broad spectrum of regulatory compliance, quality improvement, and patient safety, making them a sought-after consultant in the healthcare industry.

Dr. Sanjay K. Srivastava is a University Distinguished Professor and Chairman of the Department of Immunotherapeutics and Biotechnology, and Associate Dean for Graduate Programs at the Texas Tech University Health Sciences Center (TTUHSC). He is also James ‘Buddy’ Davidson Endowed Professor of Pediatric Pharmacology and Oncology. Dr. Srivastava also served as the Associate Dean for Research for six years at TTUHSC. He recently received the honor to be elected as the Fellow of American Association for the Advancement of Science (AAAS), a very prestigious scientific organization. He has extensive research experience in the field of cancer chemoprevention and therapeutics. Dr. Srivastava is a serial innovator with several patents to his credit. His inventive contributions are supported by excellence in research. Named in Stanford University’s list for the World’s Top 2% Scientists for 2020 & 2021, Dr. Srivastava has a track record of being a productive scientist, authoring more than 160 research articles in high-impact journals with more than 10,000 citations and holding an H-index of 57, demonstrating just how impactful his research contributions have been over the years. His research has been funded by National Cancer Institute, NIH or other agencies, and he has received numerous prestigious awards. The major focus of his laboratory is on delineating the signaling mechanisms responsible for tumor growth, angiogenesis and metastasis in different cancer models including pancreatic, ovarian, breast, melanoma and glioblastoma. His recent research focuses on understanding the mechanism of chemotherapeutic drug resistance in melanoma, breast and glioblastoma. For the last 10+ years, he has also been repurposing existing non-cancer drugs for cancer therapy. For example, his group has shown the anticancer effects of few anti-psychotic drugs for breast cancer, brain cancer, and pancreatic cancer therapy. He also showed the anti-tumor effects of anti-malarial and anti-helminthic drugs for drug resistant breast cancer. Dr. Srivastava has mentorednumeroustrainees (undergraduate students, post-doctoral fellows and graduate students), who are now established researchers/faculty at different places. His research has been highlighted by media and news agencies. Dr. Srivastava is in the editorial board of several prestigious journals and is the member of societies including AACR, SOT, AAAS and AAPS. He serves in the grant review panels of National Institute of Health (NIH), Department of Defense and other agencies.

Arne Duebecke, born in Braunschweig, Germany, obtained his degree in Environmental Sciences from the Carl-von-Ossietzky-University in Oldenburg, Germany in 2002. The following years he worked at the Institute for Chemistry and Biology of the Marine Environment and the Max-PlanckInstitute for Marine Microbiology in the area of biogeochemistry before he changed to the realm of food sciences in 2008 by joining Quality Services International (QSI) laboratories in Bremen, Germany. At QSI he worked on pyrrolizidine, tropane and ergot alkaloids in honey and other bee products as well as plant materials, including tea (Camellia sinensis), herbs and spices. During that period he took different roles in project management, research & development and quality management. In 2013 he moved the focus to the verification of authenticity and detection of adulteration of foodstuffs. The methods employed comprised enzymatic approaches, SIRA, HPLC, LCMS, HRMS, GC-MS, NMR and multivariate statistics. In 2017 Arne took the lead of the newly founded Tentamus Center for Food Fraud (TCF²). From beginning 2022 to early 2024 he additionally was managing director of Tentamus chelab GmbH in Hemmingen, Germany, a lab specialized on analysis of fruit and vegetable juices. He presented latest QSI, Chelab and TCF² research at many international conferences and also prepared a number of publications for trade journals and peer-reviewed journals. He is member of the GDCh (German Chemical Society), AOAC International, IAFP (International Association for Food Protection) and ACAFP (African Continental Association for Food Protection).

Dr. Gert Fricker is Professor at the Institute of Pharmacy and Molecular Biotechnology in the Faculty of Engineering Sciences, Ruprecht-Karls University Heidelberg, Germany. After studying chemistry and medicine at the University of Freiburg, Germany, and finishing his PhD in 1986, he worked as Post-Doc in the Department of Clinical Pharmacology, University Hospital Zurich, Switzerland. In 1988 he became research scientist at Sandoz Pharma AG, Basel, Switzerland. 1995, G. Fricker was appointed Professor at the University of Heidelberg, 2002 he became chair for Pharmaceutical Technology and Director at the Institute of Pharmacy and Molecular Biotechnology. In addition to his university affiliation, G. Fricker is Head of the Technology Transfer Center Biopharmacy and Analytics in Heidelberg, a service center for Pharma Industry. In 2016, he was initiator of the university spin-off company HeiDelTec GmbH dealing with oral peptide drug delivery. His main research interests are the permeation of drugs across barrier tissues with particular emphasis on intestine and blood brain barrier as well as the development of drug targeting systems by colloidal drug carriers.

Sonia Laneri has her expertise in chemical synthesis of drugs, in particular heterocyclic nucleus and pseudohormones, their characterisation by spectroscopic methods and their therapeutic application. In addition, she is head of the Centre for Cosmetic Science Research at the Department of Pharmacy, University of Naples Federico II, where in vivo and ex vivo efficacy studies on cosmeceuticals have been conducted. Her latest research work is focused on new upcycled active ingredients for dermocosmetic use.

Raffaele Pilla, Pharm.D., Ph.D., Doctor Europaeus, received his Master’s degree in Pharmacy at G. d’Annunzio University in Chieti-Pescara, Italy in 2005, where he also served internships at the Cell Physiology Laboratory and Molecular Biology Laboratory. Prior to his degree, he was an Erasmus Student at Faculté de Pharmacie de Reims in Reims, France. He received his Doctor Europaeus in 2010 from Pitié-Salpétrière Institute in Paris, France. Also in 2010, he received his Ph.D. in Biochemistry, Physiology, and Pathology of Muscle at G. d’Annunzio University in Chieti-Pescara, Italy. He was hired as a Postdoctoral Scholar in the Department of Pharmacology and Physiology at the University of South Florida in Tampa, on two research grants respectively funded by the Office of Naval Research (US Navy) and Divers’ Alert Network. He has written and lectured widely on his experiences. Dr. Pilla has been involved in ongoing research at the University of South Florida with the use of ketone esters. The initial work, funded by the Office of Naval Research, focused on using ketone esters to prevent CNS oxygen toxicity. Dr. Pilla is working to coordinate efforts in the United States and Italy to expand the ketone ester research to other conditions such as epilepsy and cancer and its use as an alternative metabolic fuel. Dr. Pilla has also served extensively in various international medical missions, orphan and homeless programs, emergency medicine rescue and training, and animal rescue and fostering. He is fluent in Italian, English, French, and Spanish. He has a special interest in journalism and photography, and he enjoys sailing, SCUBA diving, ultralight airplane piloting, soccer, volleyball, jogging, and motorcycles.

Will be updated soon...

In 2016, Mrs. Asst. Univ. Ana Maria Vlasceanu. Pharm., PhD started working as an assistant professor at the University of Medicine and Pharmacy of Bucharest's Department of Toxicology. Between 2014 and 2015, she was a PhD student with a scholarship within the Excelis Project (Excellence in scientific, interdisciplinary, doctoral, and postdoctoral research, in the economic, social and medical fields - Excelis, POSDRU/159/1.5/S/138907) (scholarship obtained through competition, project completion in first place). In 2015, she graduated with a master's degree in pharmacology and toxicology from the University of Medicine and Pharmacy in Craiova, Faculty of Pharmacy (grade 10), dissertation: "The influence of the constituents of cigarette smoke on the metabolism of some xenobiotics". She became a specialist pharmacist in the Pharmaceutical Laboratory specialty following training courses through residency in the period 2016-2019 and passing the exam in the September 2019 session. She obtained the scientific title of PhD in the field of Pharmacy, specialty Toxicology, defending, in 2019, the doctoral thesis, appreciated with the Suma cum laude distinction. The didactic activity consists of the guidance of practical works and the assessment of students from the IV and V study years, the guidance of bachelor's works. The scientific and research activity of Mrs. Asst. Univ. Ana Maria Vlăsceanu. Pharm., PhD includes 3 book chapters published as a co-author in international publishing houses, a book/study aid for students, published as a co-author in a national publishing house recognized CNCSIS, 11 published works (of which 8 in ISI rated/indexed journals), 5 papers presented at international scientific events, published as abstract in ISI indexed journals, 3 papers presented at other scientific events. Mrs. Asst. Univ. Ana Maria Vlăsceanu. Pharm., PhD attended a series of specialization courses in Toxicology and Pharmacy (European Society of Toxicology in Vitro, ESTIV, Applied In Vitro Toxicology Course, April 14-19, 2019, Bucharest; "Currents in medico-legal toxicology", Murighiol, May 25, 2017, course held by the board members of The International Association of Forensic Toxicologists, TIAFT, within CNML 2017; "Multidisciplinary pharmacotherapeutic approach"). The preoccupation for the scientific activity is also supported by the two editions of the National Congress of Toxicology, with international participation (Bucharest, Romania 2015 and 2017), that Mrs. Asst. Univ. Ana Maria Vlăsceanu Pharm., PhD contributed as President of the Organizing committee. The research carried out in the scientific activity focused on areas such as pharmacotoxicological testing methods (experimental models for testing the action and toxicity of some medicinal or toxic substances), Food Safety, spectrofluorimetric studies on cell suspensions, following changes in some cellular parameters, addiction (analytical diagnosis, optimization), Ecotoxicology.

Doctor specializing in clinical toxicology with deep interest in the pharmaceutical industry. Skills: � Deep understanding of pharmacology and human physiology. � Knowledge of the principles and practices of clinical medicine. � Familiarity with local and international regulations and standards related to pharmacovigilance. � Ability to stay up to date on changes in laws and regulations. � Experience in identifying, evaluating and managing adverse drug events (ADEs) and other safety issues. � Knowledge of the procedures for reporting adverse events to health authorities. � Passion for improving public health through pharmaceutical solutions. With interest in continuing my professional career in the pharmaceutical industry both in the area of ??Pharmacovigilance and/or in the wonderful profession of MSL/scientific liaison doctor. Knowledge: � I have extensive knowledge of therapeutics and diseases. � I aim to foster meaningful scientific exchanges with prominent leaders in the external medical and scientific community. � I focus on providing accurate and balanced scientific information to leaders on topics related to areas of interest. � I am in charge of answering queries that range from general scientific questions to specific questions about the products handled.

Dr. Tugce Uskur was born in Istanbul, Turkey, and completed her master's and doctoral degrees in Medical Pharmacology at the Cerrahpa?a Faculty of Medicine. She is currently serving as an Assistant Professor in the Department of Medical Pharmacology at K?rklareli University Faculty of Medicine. Dr. Uskur's research interests include pharmacology, psychopharmacology, toxicology, and pharmacotherapies in emergency medicine, with a particular focus on drug interactions and the clinical impacts of drug levels. She has contributed to national and international journals and has presented at various conferences and seminars. Dr. Uskur is actively engaged in research on common poisonings and treatment methods in emergency services, making significant contributions to these fields and participating in numerous scientific projects. Additionally, she is actively involved in the education of students, emphasizing the training of the next generation of health professionals.

Ahmet has completed his bachelor in Chemical and Mechanical Engineering and has been working for about 23 years in the field of textile management with various reputed retail brands and training across Europe and US. Ahmet has conducted over 2800 audits on behalf of international brand clients over the last 12 years. Being a HIGG FEM trainer and Chemical specialist verifier, Ahmet has conducted more than 250 Higg verifications in 3 years. Ahmet has been working for a long time as a sustainability profession in the textile and apparel industry. He has conducted training for sustainability practitioners in the industry in the Istanbul Technical University as an expert. Ahmet is certified by the Republic of Türkiye Ministry of Energy and Natural Resources for Energy management. Dyeing machines isolation feasibility on energy Management for Europe Brands in Textile , Energy Management and Energy ministry consumption declarations for different organizations, ISO 50001 feasibility, Coal, Natural Gas, LNG versus BIOMASS feasibility check are some of his noteworthy works in the field of Energy management in last 15 years.

Will be updated soon...

Will be updated soon...

Svetlana Yovinska is an assistant professor at the Department of Pharmacology and Toxicology, Medical Faculty, Medical University Sofia, Sofia, Bulgaria. She was studying medicine at the Medical Faculty of Sofia University, and was graduated in 2019. In 2019-2020, she was working in a genetic laboratory, where she gained an experience in cytogenetic analysis, and started a research on the relationship between cytogenetic abnormalities and male infertility. In 2020, she became a PhD student at the Department of Pharmacology and Toxicology. Her main research interests are in the fields of pharmacogenetics and pharmacogenomics. She conducted a research on CYP450 polymorphisms, MTHFR mutations, and other gene defects, affecting drug response, and the degree of their impact on spermatogonia failure. Currently, she is studying the impact of different pharmacogenetic defects on male infertility.